Search results
Results From The WOW.Com Content Network
In July 2020, Pfizer and BioNTech announced that two of the partners' four mRNA vaccine candidates had won fast track designation from the FDA. [124] The company began Phase II-III testing on 30,000 people in the last week of July 2020 and was slated to be paid $1.95 billion for 100 million doses of the vaccine by the US government. [ 125 ]
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich-based venture capital firm, the family office of Andreas and Thomas Strüngmann, and the present chairman of the supervisory board, Helmut Jeggle.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
Download as PDF; Printable version; From Wikipedia, the free encyclopedia. Redirect page. Redirect to: Pfizer–BioNTech COVID-19 vaccine; Retrieved from " ...
Shortly afterwards, it was announced that the EU was about to sign a deal with Pfizer worth €35 billion to provide 900 million doses of the Pfizer–BioNTech COVID-19 vaccine through 2023, with an additional 900 million doses available for purchase.
On 21 December 2020, the CHMP recommended granting a conditional marketing authorization for the Pfizer-BioNTech COVID‑19 vaccine, Comirnaty (active ingredient tozinameran), developed by BioNTech and Pfizer. [144] [145] [22] The recommendation was accepted by the European Commission the same day. [144] [146] [147] [148]
Kathrin U. Jansen (born 1958) is the former [1] Head of Vaccine Research and Development at Pfizer.She previously led the development of the HPV vaccine and newer versions of the pneumococcal conjugate vaccine (), and is working with BioNTech to create a COVID-19 vaccine using mRNA (Pfizer–BioNTech COVID-19 vaccine) that was approved for Emergency Use Authorization in the United States on ...
Özlem Türeci (Turkish pronunciation: [ˈœzlem ˈtyredʒi]; born 6 March 1967) is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. [2]